Cormorant
Portfolio in Switzerland · Taiwan · United States: 3 funded startups tracked by Uback, 2 of them in a ranking.
Portfolio on Uback3startups, 3 countries
In a ranking2ranked by AI-estimated valuation
On the Radar1eligible, not ranked
Latest deal trackedJan 2025Numab Therapeutics
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| Numab Therapeutics | #6 Switzerland | Biotech › multispecific antibodies | Series C (incl. extensions) · USD 200M · Jan 2025 | Unicorn |
| Umoja Biopharma | #10 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series C · USD 100M · Jan 2025 | Hundreds of M$ |
| AltruBio | Radar | Biotech › immune checkpoint enhancers | Series B · up to USD 225M · May 2024 | Not estimated |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
12024
22025
Co-investors
Forbion Growth · HBM Healthcare · Novo Holdings · BVF · Octagon · RTW · BlackRock · BVF Partners · RA Capital · Soleus Capital · Alexandria Venture Investments · ARK Invest · SoftBank
Investors that joined the same rounds, as reported by public sources.
Last updated: Oct 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.